18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Biyun Wang, MD30 enrolled

Overview

Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the response to pyrotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

Study Type

OBSERVATIONAL

Enrollment

Conditions

HER2-positive Breast Cancer

Interventions

PyrotinibDRUG

Pyrotinib 400mg po qd

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically confirmed HER2 positive breast cancer * Treated with Pyrotinib in the metastatic settings * Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine were included in this study Exclusion Criteria: * Incomplete medical history * Loss of follow up

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Time frame: Through study completion, an expected average of 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.